ATE407147T1 - Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein - Google Patents

Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein

Info

Publication number
ATE407147T1
ATE407147T1 AT03705004T AT03705004T ATE407147T1 AT E407147 T1 ATE407147 T1 AT E407147T1 AT 03705004 T AT03705004 T AT 03705004T AT 03705004 T AT03705004 T AT 03705004T AT E407147 T1 ATE407147 T1 AT E407147T1
Authority
AT
Austria
Prior art keywords
glycoprotein
neutralizing activity
monoclonal antibodies
activity against
human monoclonal
Prior art date
Application number
AT03705004T
Other languages
German (de)
English (en)
Inventor
Roberto Burioni
Original Assignee
Roberto Burioni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberto Burioni filed Critical Roberto Burioni
Application granted granted Critical
Publication of ATE407147T1 publication Critical patent/ATE407147T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT03705004T 2002-01-30 2003-01-29 Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein ATE407147T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002RM000049A ITRM20020049A1 (it) 2002-01-30 2002-01-30 Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.

Publications (1)

Publication Number Publication Date
ATE407147T1 true ATE407147T1 (de) 2008-09-15

Family

ID=11456013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03705004T ATE407147T1 (de) 2002-01-30 2003-01-29 Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein

Country Status (17)

Country Link
US (2) US20050084845A1 (enExample)
EP (1) EP1476468B9 (enExample)
JP (1) JP4287280B2 (enExample)
KR (1) KR101002791B1 (enExample)
CN (1) CN1856508A (enExample)
AT (1) ATE407147T1 (enExample)
AU (1) AU2003208000B2 (enExample)
CA (1) CA2474801C (enExample)
DE (1) DE60323333D1 (enExample)
DK (1) DK1476468T3 (enExample)
EA (1) EA009861B1 (enExample)
ES (1) ES2314179T3 (enExample)
IT (1) ITRM20020049A1 (enExample)
NZ (1) NZ534922A (enExample)
RU (1) RU2004126238A (enExample)
WO (1) WO2003064473A2 (enExample)
ZA (1) ZA200406187B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
WO2008107187A1 (en) * 2007-03-06 2008-09-12 Ribovax Biotechnologies S.A. Antibodies specific for rubella virus
CN101809033A (zh) 2007-07-25 2010-08-18 日本国立感染症研究所 对丙型肝炎病毒(hcv)感染具有抑制活性的抗体和其用途
AU2008341542B2 (en) * 2007-12-17 2014-12-04 Medical Research Council Technology Hepatitis C virus antibodies
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
WO2010035292A1 (en) * 2008-09-24 2010-04-01 Natimab Therapeutics S.R.L. The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
ITTO20080964A1 (it) * 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
CN102596996B (zh) 2009-10-30 2014-06-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
JP6095984B2 (ja) 2010-03-01 2017-03-15 アニョロ, ヴィンセントAGNELLO, Vincent Ｈｃｖ感染患者のクリオグロブリン血症性血管炎およびｂ細胞悪性腫瘍のための予後マーカー
CN104119436B (zh) * 2013-04-27 2016-12-28 中国科学院上海生命科学研究院 抗丙型肝炎病毒的中和性全人单克隆抗体
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
KR20180001380U (ko) 2016-10-31 2018-05-10 대우조선해양 주식회사 해양구조물의 발로 작동시키는 캡스탄
CN118440204A (zh) 2019-12-27 2024-08-06 凯奥目生物科学株式会社 抗cdcp1抗体
US20230312744A1 (en) 2020-09-02 2023-10-05 The University Of Tokyo Modulatory Substance of Tumor Immune Microenvironment, and Preventive, Diagnostic and/or Therapeutic Utilization of the Same
US20250375498A1 (en) 2022-07-28 2025-12-11 The University Of Tokyo Neurotrimin function inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951646B1 (en) * 1998-07-21 2005-10-04 Genmab A/S Anti hepatitis C virus antibody and uses thereof
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
AU2001273363A1 (en) 2000-07-12 2002-01-21 General Instrument Corporation Method and apparatus for downloading objects via an inband channel with minimal subscriber impact
JP2004524829A (ja) * 2000-12-01 2004-08-19 アメリカ合衆国 Ｃ型肝炎ウイルスのｅ２糖タンパク質に特異的なモノクローナル抗体、ならびにｃ型肝炎の診断、治療、および予防におけるそれらの使用

Also Published As

Publication number Publication date
KR20040077745A (ko) 2004-09-06
EP1476468B1 (en) 2008-09-03
WO2003064473A2 (en) 2003-08-07
EA200401081A1 (ru) 2005-10-27
US7727529B2 (en) 2010-06-01
JP4287280B2 (ja) 2009-07-01
JP2005531286A (ja) 2005-10-20
ITRM20020049A1 (it) 2003-07-30
CA2474801A1 (en) 2003-08-07
NZ534922A (en) 2008-07-31
EA009861B1 (ru) 2008-04-28
ES2314179T3 (es) 2009-03-16
CA2474801C (en) 2012-03-20
WO2003064473A3 (en) 2003-12-24
US20080241162A1 (en) 2008-10-02
US20050084845A1 (en) 2005-04-21
ZA200406187B (en) 2006-06-28
DE60323333D1 (de) 2008-10-16
EP1476468B9 (en) 2009-04-08
AU2003208000B2 (en) 2010-05-20
CN1856508A (zh) 2006-11-01
EP1476468A2 (en) 2004-11-17
RU2004126238A (ru) 2005-04-20
KR101002791B1 (ko) 2010-12-21
ITRM20020049A0 (it) 2002-01-30
DK1476468T3 (da) 2009-01-19

Similar Documents

Publication Publication Date Title
ATE407147T1 (de) Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein
EA201300022A1 (ru) Терапевтическое человеческое моноклональное антитело против il-1r1
DK1383785T3 (da) Rekombinant tumorspecifikt antistof og anvendelse deraf
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
DE60220719D1 (de) Antikörper gegen das muc18-antigen
UA109633C2 (uk) Антитіло людини проти тканинного фактора
ATE471946T1 (de) Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
CY1118429T1 (el) Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
CR8108A (es) Tratamiento con anticuerpos anti-vegf
EA200300628A1 (ru) Соединения, специфические к аденозиновому a, aи aрецептору, и их применение
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
EP1467757A4 (en) USE OF ANTIBODIES TO THE MUC18 ANTIGEN
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
WO2004018519A3 (en) Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
EP1748075A4 (en) RECOMBINANT CHEMOKIN ANTIGEN VACCINE
WO2001072334A3 (en) Methods for treating disease with antibodies to cxcr3
WO2006113723A3 (en) Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
WO2023159061A3 (en) Human monoclonal antibodies targeting the s2 subunit of the sars-cov-2 spike protein
WO2004035003A3 (en) Therapeutic adjuvant
EP4623992A3 (en) Antibodies specifically binding to human il-1r7

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties